Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1023 participants.
Also called NCT03112707
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,023 participants
- Sponsor
- Humanitas Hospital, Italy
- Registry
-
NCT03112707
-
- Other papers using this trial's data
- Early oral anticoagulation monotherapy after PCI: Insights from the POEM trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Italy
- Registry status
- Unknown status
Technical summary
Registry record NCT03112707. Allocation not applicable; no masking; primary purpose treatment. Start 2017-04-14 (actual); primary completion 2020-05-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT
- Acronym
- POEM
- Condition
- Coronary Artery Disease
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- P2Y12 inhibitor
- Lead sponsor
- Humanitas Hospital, Italy
Record details
- Record id
cardio:ct-nct03112707- Content hash
861928fdd32f596bac3cde9da1ea1a5e5d766fa7b6f394192f632a91fb3c125b